Solid Biosciences Inc SLDB
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Solid Biosciences to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference
Solid Biosciences Reports Third Quarter 2026 Financial Results and Provides Business Updates
Solid Biosciences Announces European Commission Orphan Designation for SGT-212 and Continued Progress in the FALCON Trial in Friedreich’s Ataxia
Solid Biosciences to Present Research Across Gene Therapy Development, Delivery and Manufacturing at ESGCT 2026
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Solid Biosciences to Participate at Upcoming Investor Conferences
Trading Information
- Previous Close Price
- $6.52
- Day Range
- $6.01–6.62
- 52-Week Range
- $3.79–11.45
- Bid/Ask
- $5.58 / $6.20
- Shares Outstanding
- 111.61M
- Market Cap
- $662.65M
- Volume/Avg
- 1M / 1M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Solid Biosciences Inc is a life sciences company focused on advancing a portfolio of current and future gene therapy candidates, including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, and additional assets for the treatment of genetic cardiac and neuromuscular diseases. The majority of its current programs are designed to treat these diseases with gene transfer products. The company operates in a single segment, developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 121
- Website
- https://www.solidbio.com
Valuation
Metric | SLDB |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 2.01 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric | SLDB |
|---|---|
Quick Ratio | 11.46 |
Current Ratio | 11.99 |
Interest Coverage | — |
Quick Ratio
SLDB
Profitability
Metric | SLDB |
|---|---|
Return on Assets (Normalized) | −53.70% |
Return on Equity (Normalized) | −62.78% |
Return on Invested Capital (Normalized) | −62.05% |
Return on Assets
SLDB
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|#z%QPtt | LOCK|!gwb | $138B | |||
| Moderna Inc MRNA | LOCK|K%?wVCm | LOCK|nm | $96B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|W#SqGQ | LOCK|bcTj | $93B | |||
| argenx SE ADR ARGX | LOCK|wB?!Y@ | LOCK|@Z$ | $58B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|?BG#VkW | LOCK|Ms | $48B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|R$p&&JJl | LOCK|&TRkJ | $30B | |||
| Incyte Corp INCY | LOCK|z&V$PtN | LOCK|C% | $24B | |||
| BioNTech SE ADR BNTX | LOCK|t$w!Z?H | LOCK|>n | $21B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|lt$$&hg | LOCK|p@!^ | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|Db%^m> | LOCK|X&t | $15B |
United States